The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)

The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)

Upadacitinib (UPA), a JAK inhibitor, is a new therapeutic option that allows patients with insufficient response to therapy with basic anti-inflammatory drugs (DMARDs) or genetically engineered biological drugs (GEBDs) to achieve the goals of therapy for rheumatoid arthritis (RA). Despite the availa...

Full description

Saved in:
Bibliographic Details
Main Authors: V. N. Amirjanova, A. E. Karateev, E. Y. Pogozheva, A. A. Baranov, V. I. Mazurov, R. R. Samigullina, O. N. Anoshenkova, N. A. Lapkina, T. Yu. Grineva, E. L. Nasonov, A. M. Lila
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-10-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
upadacitinib
efficacy
quality of life
Online Access:https://rsp.mediar-press.net/rsp/article/view/3077
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://rsp.mediar-press.net/rsp/article/view/3077

Similar Items